HR and breast cancer: In the past few years, PIK3CA has emerged as a promising target for BC treatment, with alpelisib and fulvestrant receiving approval for the treatment of PIK3CA-mutated, endocrine-resistant HR+/HER2− locally-advanced or metastatic BC (De Mattos-Arruda 2020).